Over time, the liver acquires the ability to regulate immune responses against harmless antigens, thereby forming an immune‐tolerant microenvironment that affects HCC development and treatment.[35] In addition, whether a molecule can become a target for cancer therapy depends on two necessary features: TME‐specific overexpression and immune‐inhibitory function.[36] Single‐cell sequencing landscapes and bulk sequencing analyses revealed a significant correlation between RECQL4 and the decreased recruitment of DCs and CD8+ T cells. The gene discussed is CD8A; the disease is hepatocellular carcinoma.